Disclaimer: In accordance with HSA regulations in Singapore, we are unable to mention specific brand names on this page.
However, the popular once-weekly semaglutide injection is now available at our clinic. Enquire now via WhatsApp to speak with our team and learn more.
Liraglutide, a prescription-based daily injectable medication available in Singapore, is specifically developed for weight management. As a glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide plays a key role in controlling appetite and reducing caloric intake, making it a valuable option in obesity treatment.
This treatment is particularly beneficial for individuals who have not achieved desired weight loss results through diet and exercise alone. Clinical evidence supports its inclusion in comprehensive weight management plans, establishing liraglutide as a reliable option in the medical management of obesity.
Patients using liraglutide injections generally experience a reduction in body weight of approximately 5% after 4 months of regular use. This reduction can increase to around 10% after 6–8 months and potentially reach 12% or more after a year of consistent treatment.
Liraglutide has demonstrated substantial effectiveness in promoting weight loss. Clinical trials indicate that combining liraglutide with a reduced-calorie diet and increased physical activity can result in significant weight reduction, particularly for individuals dealing with obesity or overweight conditions.
Liraglutide mimics the GLP-1 hormone, which plays a crucial role in appetite control. By stimulating GLP-1 receptors, it reduces hunger and enhances satiety, helping patients lower overall calorie intake and adhere to weight loss diets.
Using liraglutide for weight loss positively impacts various health indicators. Notable improvements include reduced blood pressure, better cholesterol levels, and enhanced blood sugar control, particularly beneficial for those with type 2 diabetes.
Liraglutide is administered through a pre-filled injection pen, offering ease of use and convenience. The injections can be self-administered in areas such as the abdomen, thigh, or upper arm, making it easy to incorporate into daily routines.
Liraglutide is not just a temporary solution but part of a long-term strategy for weight management. When integrated with a balanced diet and regular exercise, it helps maintain weight loss over extended periods.
In addition to physical health benefits, liraglutide use has been associated with positive psychological outcomes, such as improved self-esteem and reduced symptoms of depression and anxiety, which are often linked to body weight concerns.
GLP-1 receptor agonist injections target the biological processes that contribute to weight gain, insulin resistance, and metabolic dysfunction. These medications work through several key mechanisms that support effective and sustained weight loss, while also improving glucose regulation in individuals with or without type 2 diabetes.
In a comprehensive 56-week clinical study, adults with obesity or overweight conditions, accompanied by related health issues, underwent treatment with liraglutide. The results showed an average weight loss of approximately 9.5kg, highlighting its role in effective weight management.
A significant number of participants reported more than 5% to 10% loss from their baseline body weight after using liraglutide. This level of weight reduction is clinically significant and contributes to overall health improvement.
In addition to aiding weight loss, liraglutide has been effective in reducing waist circumference, a critical factor in lowering risks associated with obesity-related health issues.
In practical applications, patients using liraglutide alongside lifestyle changes experience an average weight loss of around 8kg over six months. Many achieve reductions exceeding 5% or 10% of their initial body weight.
The benefits of liraglutide extend beyond weight loss. Improvements in cardiometabolic risk factors, such as blood glucose levels and blood pressure, enhance its overall effectiveness as a weight loss treatment.
Liraglutide works by mimicking the GLP-1 hormone, which regulates appetite. Its active component activates GLP-1 receptors, reducing hunger and enhancing feelings of fullness. This helps decrease overall calorie consumption and supports adherence to weight loss plans.
A key function of liraglutide is slowing the gastric emptying process, prolonging the feeling of fullness and reducing food intake. This slow digestion process is instrumental in enhancing the efficacy of weight loss treatments.
Liraglutide significantly influences insulin secretion by prompting the pancreas to release insulin in response to elevated blood sugar levels. Enhanced insulin secretion improves glucose absorption, which is critical for energy production.
Liraglutide also reduces the secretion of glucagon, a hormone that elevates blood sugar levels. By lowering glucagon levels, it helps maintain stable blood sugar levels, benefiting individuals with diabetes and supporting effective weight management.
Understanding who is best suited for liraglutide weight loss injections is key to its effectiveness in obesity treatment and management. Here are the primary candidates for whom this treatment is considered an appropriate solution:
GLP-1 receptor agonists are injectable medications widely used for both weight management and diabetes treatment. While they share a common mechanism of action—mimicking the GLP-1 hormone to regulate appetite and blood sugar levels—they differ in their primary applications, dosing schedules, and effectiveness.
Some GLP-1 receptor agonists are specifically prescribed for weight loss and are often approved for individuals with obesity or overweight conditions, particularly those with weight-related health issues such as type 2 diabetes or hypertension. These medications focus on appetite regulation, helping users consume fewer calories while feeling fuller for longer.
Key Features:
Other GLP-1 receptor agonists are primarily intended for managing type 2 diabetes. These medications help regulate blood sugar levels by increasing insulin secretion and reducing glucagon release, improving overall glycemic control. While weight loss may occur, it is generally a secondary benefit rather than the primary goal.
Key Features:
All GLP-1 receptor agonists mimic the natural GLP-1 hormone, but their effects vary depending on their formulation and intended use. For weight loss, the focus is on appetite suppression and slowing gastric emptying, while diabetes-focused treatments emphasize insulin secretion and blood sugar stabilization.
Choosing the right GLP-1 receptor agonist requires a thorough medical evaluation. Your healthcare provider will consider factors such as your medical history, primary health goals, and lifestyle preferences to recommend the most suitable option.
Initial Consultation: Assessing Suitability for Liraglutide
Starting the Liraglutide Treatment
Ongoing Monitoring and Support
Managing Side Effects of Liraglutide
Periodic Assessment of Effectiveness
Long-Term Strategy with Liraglutide
By being aware of and managing potential side effects, patients can safely incorporate liraglutide into their weight loss plan. Open communication with a healthcare provider ensures a successful and healthy weight loss journey.
Liraglutide weight loss injections, a leading prescription treatment for weight management, have specific contraindications where their use may not be advisable due to potential health risks. Before starting treatment, it is crucial to consult with your doctor to thoroughly evaluate your medical history and assess suitability.
Below are the primary medical conditions that may preclude the use of liraglutide weight loss injections:
Individuals with a personal or family history of Medullary Thyroid Carcinoma should avoid using liraglutide. This precaution is due to the potential increased risk of thyroid C-cell tumors, a known complication associated with GLP-1 receptor agonist treatments.
Patients diagnosed with MEN 2, a genetic condition that can lead to endocrine tumors, are advised against using liraglutide due to potential complications related to this syndrome.
Liraglutide weight loss injections are not recommended during pregnancy or while breastfeeding. If pregnancy occurs during treatment, the medication should be discontinued to avoid potential risks to the unborn child or nursing infant.
Patients who have previously experienced severe hypersensitivity reactions to liraglutide or any other components of the injection should not use this treatment. Severe allergic responses, including anaphylaxis and angioedema, are contraindications.
Those with a history of pancreatitis should use liraglutide cautiously or avoid it altogether. Acute pancreatitis has been reported in patients using GLP-1 receptor agonists, including liraglutide, making thorough medical evaluation essential.
Patients suffering from severe gastrointestinal conditions, such as gastroparesis, should avoid liraglutide. Its effect of slowing gastric motility could exacerbate existing gastrointestinal disorders, leading to further complications.
Before starting liraglutide weight loss injections, a comprehensive medical consultation is necessary to rule out any contraindications. Your doctor will assess your medical history, conduct relevant tests, and determine if this treatment is suitable for you.
Liraglutide is a GLP-1 receptor agonist that mimics the natural hormone responsible for regulating appetite and satiety. Unlike general diet and exercise efforts, over-the-counter slimming aids, or supplements, prescription medications such as Saxenda have been clinically validated to assist with weight management.
Other GLP-1 based treatments like Wegovy and Ozempic also work through similar mechanisms but differ in dosing and indications.
Yes, GLP-1 weight loss injections such as Saxenda are specifically developed for individuals who have not achieved adequate weight loss with lifestyle modifications alone. Saxenda enhances satiety and reduces hunger, making it easier to sustain a calorie deficit.
Other GLP-1 options, including Wegovy or Mounjaro, may be considered depending on your clinical profile.
Saxenda treatment usually starts with a low initial dose to help minimise side effects such as nausea or bloating. The dose is gradually increased over several weeks to reach the therapeutic maintenance level.
This stepwise titration approach is consistent across medications like Ozempic, Mounjaro and Wegovy to improve tolerance.
Saxenda injections are typically administered daily using a fine, small-gauge needle designed for comfort. Most patients report minimal discomfort after learning proper injection techniques during the initial consultation.
Of note, Saxenda requires daily injections, while alternatives like Ozempic, Wegovy and Mounjaro offer weekly dosing schedules.
The duration of treatment depends on your weight loss goals, health conditions, and overall management strategy. Many patients continue using medications like Saxenda for an extended period to sustain weight loss, under the guidance of their doctor. Long-term use strategies are similarly applied to GLP-1 therapies like Wegovy and Ozempic.
Weight regain is a possibility after stopping Saxenda treatment if healthy lifestyle habits are not maintained. This applies across all GLP-1 therapies, including Ozempic, Wegovy, and Mounjaro.
Sustained lifestyle modifications, nutritional guidance, and regular follow-up are crucial to prevent rebound weight gain.
Progress is monitored through weight changes, body mass index (BMI) improvements, and metabolic markers. Achieving at least a 5% reduction in body weight within 4 months of starting therapy, as commonly seen with Saxenda, is generally considered a positive response.
Yes, interactions may occur with Saxenda, particularly when used alongside other diabetes treatments such as insulin or sulfonylureas. It is important to inform your doctor of all medications you are currently taking if you are considering starting Saxenda for weight management. Your doctor will assess potential interactions and adjust your treatment plan accordingly.
Saxenda and other GLP-1 therapies are not recommended for individuals with a history of Medullary Thyroid Carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or pancreatitis. This caution extends to medications including Rybelsus, Wegovy, Ozempic, and Mounjaro. Your doctor will conduct a thorough medical evaluation to ensure treatment suitability.
To maximise results from therapies such as Saxenda, Wegovy, and Ozempic, patients are advised to follow a calorie-controlled diet, maintain regular physical activity, manage stress levels, and ensure adequate sleep. These healthy lifestyle practices greatly enhance the benefits of GLP-1 therapies and support long-term weight maintenance.
Yes, GLP-1 therapies like Saxenda, Ozempic, Wegovy and Mounjaro have been shown to provide benefits beyond weight loss. They may help improve blood sugar control, reduce blood pressure, and lower cholesterol levels. Managing these obesity-related health risks is often an integral part of a comprehensive weight loss strategy.
In accordance with Health Sciences Authority (HSA) regulations in Singapore, specific brand names for weight loss medications cannot be promoted directly in public-facing materials. However, during your private consultation, your doctor can discuss available options and recommend the most suitable treatment based on your individual health goals.
